Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
GH 
Guardant Health Inc (GH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: GH (3-star) is a STRONG-BUY. BUY since 13 days. Profits (1.54%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
24 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $59.43
Year Target Price $59.43
| 15 | Strong Buy |
| 6 | Buy |
| 3 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 18.83% | Avg. Invested days 24 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.30B USD | Price to earnings Ratio - | 1Y Target Price 59.66 |
Price to earnings Ratio - | 1Y Target Price 59.66 | ||
Volume (30-day avg) - | Beta 1.38 | 52 Weeks Range 20.14 - 53.42 | Updated Date 06/29/2025 |
52 Weeks Range 20.14 - 53.42 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.39 |
Earnings Date
Report Date 2025-06-12 | When After Market | Estimate -0.85 | Actual -0.49 |
Profitability
Profit Margin -53.82% | Operating Margin (TTM) -54.33% |
Management Effectiveness
Return on Assets (TTM) -18.64% | Return on Equity (TTM) -4584.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6905040327 | Price to Sales(TTM) 8.14 |
Enterprise Value 6905040327 | Price to Sales(TTM) 8.14 | ||
Enterprise Value to Revenue 8.92 | Enterprise Value to EBITDA -5.4 | Shares Outstanding 123888000 | Shares Floating 118676075 |
Shares Outstanding 123888000 | Shares Floating 118676075 | ||
Percent Insiders 4.6 | Percent Institutions 97.67 |
Analyst Ratings
Rating 4.5 | Target Price 59.43 | Buy 6 | Strong Buy 15 |
Buy 6 | Strong Buy 15 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Guardant Health Inc
Company Overview
History and Background
Guardant Health was founded in 2012. The company focuses on developing non-invasive cancer tests to improve outcomes across all stages of the disease.
Core Business Areas
- Precision Oncology Testing: Offers a range of liquid biopsy tests for advanced cancer patients, enabling oncologists to make informed treatment decisions based on genomic insights.
- Early Cancer Detection: Develops blood-based tests for the early detection of cancer, aiming to improve survival rates through earlier diagnosis.
- Biopharmaceutical Services: Partners with pharmaceutical companies to accelerate drug development by leveraging its liquid biopsy platform for clinical trials and biomarker discovery.
Leadership and Structure
Helmy Eltoukhy serves as co-CEO, and AmirAli Talasaz as co-CEO. The organizational structure includes departments focused on research and development, commercial operations, and clinical affairs.
Top Products and Market Share
Key Offerings
- Guardant360 CDx: A comprehensive genomic profiling test for advanced cancer patients, used to identify actionable mutations. Competitors: Foundation Medicine, Roche.
- Guardant Reveal: A liquid biopsy test for detecting residual or recurrent disease in early-stage cancer. Competitors: Exact Sciences.
- Guardant Shield: Blood test for early cancer screening. Competitors: Grail, Exact Sciences.
Market Dynamics
Industry Overview
The oncology diagnostics market is growing rapidly, driven by advancements in genomics and increasing demand for personalized medicine.
Positioning
Guardant Health is a leader in the liquid biopsy market, with a strong focus on innovation and clinical validation. They hold a competitive advantage through their comprehensive product portfolio and established relationships with oncologists.
Total Addressable Market (TAM)
The total addressable market for cancer diagnostics and screening is estimated to be substantial (greater than $50 billion). Guardant Health is targeting a significant portion of this TAM through its various tests and services.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Comprehensive product portfolio
- Established relationships with oncologists
- Robust intellectual property
Weaknesses
- High operating expenses due to research and development
- Reliance on reimbursement approvals
- Competition from larger diagnostic companies
- Cash burn
Opportunities
- Expansion into new geographic markets
- Development of new liquid biopsy tests
- Partnerships with pharmaceutical companies
- Increase in adoption of early cancer screening
Threats
- Regulatory changes
- Reimbursement challenges
- Competition from new entrants
- Economic downturn
Competitors and Market Share
Key Competitors
- Foundation Medicine (RHHBY)
- Exact Sciences (EXAS)
- Illumina (ILMN)
Competitive Landscape
Guardant Health faces competition from larger diagnostic companies with established market positions. However, Guardant Health has a strong focus on innovation and a comprehensive product portfolio, giving it a competitive edge in the liquid biopsy market.
Major Acquisitions
CellSearch Liquid Biopsy Business from Menarini
- Year: 2022
- Acquisition Price (USD millions): 70
- Strategic Rationale: Expanded access to a circulating tumor cell (CTC) platform
Growth Trajectory and Initiatives
Historical Growth: Guardant Health has experienced significant revenue growth in recent years, driven by increased adoption of its liquid biopsy tests. However, they have not yet turned profitable.
Future Projections: Analysts project continued revenue growth for Guardant Health, driven by increased adoption of its products and expansion into new markets. Profitability is anticipated in the coming years but is dependent on successful commercialization and reimbursement.
Recent Initiatives: Recent initiatives include expanding collaborations with pharmaceutical companies and advancing the development of new liquid biopsy tests for early cancer detection.
Summary
Guardant Health is a leading player in the rapidly growing liquid biopsy market, boasting a strong brand and comprehensive product portfolio. They have demonstrated strong revenue growth, however, high operating expenses and reliance on reimbursements have impacted profitability. To ensure the long-term success, Guardant Health must continue to develop new cancer tests and expand into new markets, while closely monitoring regulatory changes and managing cash burn. The recent acquisition will improve their future growth with additional market exposure.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Analyst Reports
- SEC Filings
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market data is subject to change. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Guardant Health Inc
Exchange NASDAQ | Headquaters Palo Alto, CA, United States | ||
IPO Launch date 2018-10-04 | Co-Founder, Co-CEO & Chairman Dr. Helmy Eltoukhy Ph.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 1999 | Website https://guardanthealth.com |
Full time employees 1999 | Website https://guardanthealth.com | ||
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI blood test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for adjuvant treatment and surveillance settings in early-stage cancer patients; and Smart Liquid Biopsy Platform. In addition, the company provides development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.